Ausgabe 6/2022
Inhalt (14 Artikel)
Open Access
Chronic Myeloid Leukemias (V Oehler, Section Editor)
Defining Higher-Risk Chronic Myeloid Leukemia: Risk Scores, Genomic Landscape, and Prognostication
Nur Hezrin Shahrin, Carol Wadham, Susan Branford
Chronic Myeloid Leukemias (V Oehler, Section Editor)
Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies
John Joson Ng, S. Tiong Ong
Chronic Myeloid Leukemias (V Oehler, Section Editor)
CML Resistant to 2nd-Generation TKIs: Mechanisms, Next Steps, and New Directions
Emilia Scalzulli, Ida Carmosino, Maria Laura Bisegna, Maurizio Martelli, Massimo Breccia
Health Economics (N Khera, Section Editor)
Value in Myeloma Care: Myth or Reality
Evguenia Ouchveridze, Katherine Berger, Ghulam Rehman Mohyuddin
Health Economics (N Khera, Section Editor)
Precision Medicine in Myeloid Malignancies: Hype or Hope?
Shristi Upadhyay Banskota, Nabin Khanal, Rosalyn I. Marar, Prajwal Dhakal, Vijaya Raj Bhatt
Health Economics (N Khera, Section Editor)
Prevalence and Determinants of Return to Work as a Patient-Centered Outcome in Survivors of Hematopoietic Cell Transplantation
Neel S. Bhatt
Open Access
Health Economics (R Mesa)
Progress and Challenges in Survivorship After Acute Myeloid Leukemia in Adults
Ginna Granroth, Nandita Khera, Cecilia Arana Yi
Germline Predisposition to Myeloid Neoplasms (M Patnaik, Section Editor)
Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms
Anmol Baranwal, Christopher N. Hahn, Mithun Vinod Shah, Devendra K. Hiwase
Germline Predisposition to Myeloid Neoplasms (M Patnaik, Section Editor)
Pediatric Germline Predisposition to Myeloid Neoplasms
Christineil Thompson, Sydney Ariagno, Mira A. Kohorst
Germline Predisposition to Myeloid Neoplasms (M Patnaik, Section Editor)
Approach Toward Germline Predisposition Syndromes in Patients with Hematologic Malignancies
Himachandana Atluri, Yoheved S. Gerstein, Courtney D. DiNardo
T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor)
Bispecific Antibodies for the Treatment of Multiple Myeloma
Scott R. Goldsmith, Shawn Streeter, Fahrettin Covut
T-Cell and Other Lymphoproliferative Malignancies (R Mesa, Section Editor)
Circulating Tumor DNA in Lymphoma
Swetha Kambhampati, Jasmine Zain
Multiple Myeloma (Prashant Kapoor, Section Editor)
The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma
Arleigh McCurdy, Alissa Visram
Myeloproliferative Neoplasms (P Bose, Section Editor)
Molecular Pathogenesis of Myeloproliferative Neoplasms
Benjamin Rolles, Ann Mullally